CJC-1295

A synthetic analog of growth hormone-releasing hormone, studied in two variants with different durations of action.

CJC-1295 is a stabilized analog of the body's own GHRH, studied in the context of the growth hormone axis. It exists in two variants: without DAC (Drug Affinity Complex), which has a short duration of action, and with DAC, which achieves a substantially extended duration through binding to serum albumin. Available human data come mainly from early clinical research in healthy adults.

Evidence

• Two randomized, placebo-controlled trials in healthy adults with step-wise increasing amounts: a single injection of CJC-1295 with DAC raised growth hormone levels for several days and IGF-1 levels for 9 to 11 days. Teichman et al. 2006, Journal of Clinical Endocrinology & Metabolism, PMID 16352683
• A follow-up analysis of the same subjects found that pulsatile growth hormone release was preserved even under the extended stimulation from CJC-1295 with DAC. Ionescu & Frohman 2006, Journal of Clinical Endocrinology & Metabolism, PMID 17018654

Frequently asked questions

What is the difference between CJC-1295 with and without DAC
Without DAC, the peptide is broken down within minutes, producing a short, pronounced hormone pulse. With DAC, a chemical anchor binds to albumin in the blood, extending the duration to several days, while studies indicate the pulsatile release pattern is preserved.

Is CJC-1295 an approved medication
No. CJC-1295 is not approved as a medication in the EU or the US and is sold exclusively as a research chemical for laboratory use.

What is CJC-1295 studied for in research
CJC-1295 is studied in the context of the growth hormone axis, particularly regarding the body's own release of growth hormone and the resulting IGF-1 production in the liver.

Documented prices

List prices excluding shipping and discounts. Currency and product variants must be compared separately. Availability and delivered batch have not been verified.